Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 3

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 2(3)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03954041Phase 2Terminated

A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

Role: lead

NCT02864953Phase 3Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Role: lead

NCT01268683Phase 1Completed

Glyburide Advantage in Malignant Edema and Stroke Pilot

Role: lead

NCT01794182Phase 2Completed

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

Role: lead

NCT01454154Phase 2Completed

Glyburide (RP-1127) for Traumatic Brain Injury (TBI)

Role: lead

All 5 trials loaded